Savara (NASDAQ:SVRA) Given New $9.00 Price Target at HC Wainwright

Savara logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright lowered Savara’s price target from $10 to $9 but maintained a Buy rating; the new target implies 109.21% upside from the prior close.
  • Savara shares fell 17.4% to $4.30 on Friday. Analysts’ consensus rating is Moderate Buy, with an average price target of $10.14.
  • The company reported a quarterly loss of $0.17 per share, slightly better than analysts’ estimate of a $0.18 loss.
  • MarketBeat previews top five stocks to own in December.

Savara (NASDAQ:SVRA - Get Free Report) had its price objective lowered by research analysts at HC Wainwright from $10.00 to $9.00 in a research note issued to investors on Friday, Benzinga reports. The firm currently has a "buy" rating on the stock. HC Wainwright's price objective would indicate a potential upside of 109.21% from the company's previous close.

Several other brokerages also recently commented on SVRA. Citigroup restated a "market outperform" rating on shares of Savara in a research note on Wednesday, October 7th. Royal Bank Of Canada set a $10.00 price target on shares of Savara in a report on Wednesday, October 7th. Wall Street Zen lowered shares of Savara from a "hold" rating to a "sell" rating in a research report on Sunday, October 4th. JPMorgan Chase & Co. began coverage on shares of Savara in a research note on Wednesday, October 7th. They set an "overweight" rating and a $12.00 price objective for the company. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Savara in a report on Thursday, October 15th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Savara currently has an average rating of "Moderate Buy" and a consensus target price of $10.14.

Check Out Our Latest Research Report on SVRA

Savara Trading Down 17.4%

NASDAQ SVRA traded down $0.91 during trading hours on Friday, hitting $4.30. 10,998,150 shares of the company's stock were exchanged, compared to its average volume of 1,930,906. The stock has a 50-day simple moving average of $4.88 and a 200 day simple moving average of $5.32. The firm has a market cap of $949.11 million, a price-to-earnings ratio of -7.01 and a beta of 0.32. The company has a current ratio of 8.55, a quick ratio of 8.55 and a debt-to-equity ratio of 0.28. Savara has a 1-year low of $4.00 and a 1-year high of $7.01.

Savara (NASDAQ:SVRA - Get Free Report) last issued its quarterly earnings results on Monday, November 9th. The company reported ($0.17) EPS for the quarter, topping analysts' consensus estimates of ($0.18) by $0.01. On average, equities analysts forecast that Savara will post -0.68 EPS for the current fiscal year.

Institutional Trading of Savara

Several institutional investors and hedge funds have recently bought and sold shares of SVRA. Sterling Capital Management LLC raised its position in shares of Savara by 842.8% in the 3rd quarter. Sterling Capital Management LLC now owns 5,063 shares of the company's stock worth $26,000 after acquiring an additional 4,526 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in Savara in the third quarter worth $54,000. Principal Financial Group Inc. purchased a new position in Savara during the first quarter valued at $57,000. Quarry LP boosted its holdings in shares of Savara by 6,524.4% during the 3rd quarter. Quarry LP now owns 11,924 shares of the company's stock valued at $62,000 after buying an additional 11,744 shares in the last quarter. Finally, Sequoia Financial Advisors LLC purchased a new stake in shares of Savara in the 2nd quarter worth about $69,000. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Savara Company Profile

(Get Free Report)

Savara is a biopharmaceutical company focused on developing treatments for serious and rare respiratory diseases. The company is based in the United States and concentrates its research and development efforts on conditions with limited treatment options. Savara's lead product candidate is molgramostim, an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). It has been developed as a potential treatment for autoimmune pulmonary alveolar proteinosis, a rare lung disease in which the buildup of material in the air sacs can impair breathing.

See Also

Analyst Recommendations for Savara (NASDAQ:SVRA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Savara Right Now?

Before you consider Savara, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Savara wasn't on the list.

While Savara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines